Le Lézard
Classified in: Ebola virus, Science and technology
Subject: ACC

Fagerhult Publishes Prospectus Supplement Relating to the Rights Issue


HABO, Sweden, May 13, 2019 /PRNewswire/ -- Prospectus supplement relating to the rights issue in Aktiebolaget Fagerhult ("Fagerhult") has today been approved and registered by the Swedish Financial Supervisory Authority, and is available on Fagerhult's website, www.fagerhultgroup.com, as well as on Handelsbanken's website for prospectuses, www.handelsbanken.se/prospekt.

Financial and legal advisor

Handelsbanken Capital Markets is financial advisor in connection with the rights issue. Wesslau Söderqvist Advokatbyrå and Vinge are legal advisors. 

Aktiebolaget Fagerhult (publ)

For further information, please contact:

Bodil Sonesson CEO, mobile: +46 72223 7602 e-mail: [email protected]

Michael Wood CFO, mobile: +46 73 087 46 47 e-mail: [email protected]

IMPORTANT INFORMATION

This press release is not an offer to subscribe for shares in Fagerhult and investors should not subscribe for or purchase any securities, except on the basis of information provided in the coming prospectus.

This press release may not be made public, released or distributed, directly or indirectly, in or into the United States, Australia, Japan or Canada or in any other jurisdiction in which the distribution of this press release would be unlawful. Further, this press release does not constitute an offer to sell new shares, paid subscribed for shares ("BTA") or subscription rights to any person in any jurisdiction in which it is unlawful to make such offer to such person or where such action would require additional prospectuses, registration or other measures other than those pursuant to Swedish law. The prospectus, application form and other documents associated with the rights issue may not be distributed in or to any country where such distribution or the rights issue would require such measures set forth in the preceding sentence or be in violation of the regulations of such country.

The new shares, BTAs and subscription rights have not been recommended or approved by any United States federal or state securities commission or regulatory authority. No new shares, BTAs, subscription rights or other securities issued by Fagerhult have been or will be registered under the U.S. Securities Act of 1933, as amended, or under the securities legislation in any state of the United States, and may not be offered, exercised or sold in the United States absent registration or an applicable exemption from registration requirements. There is no intention to register any portion of the offering in the United States or to conduct a public offering of securities in the United States.

The Company has not authorised any offer of the securities referred to herein to the public in any country in the European Economic Area ("EEA") other than Sweden. In other member states in the EEA, the securities may only be offered to (a) any legal entity which is a qualified investor as defined in the Directive 2003/71/EC (the "Prospectus Directive"); or (b) any person falling within Article 3(2) of the Prospectus Directive.

In the United Kingdom, this communication is only being distributed to, and is only directed at "qualified investors" (as defined in section 86(7) of the Financial Services and Markets Act 2000) who are (i) investment professionals falling within the meaning of Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the "Order"); or (ii) persons falling within Article 49(2)(a) to (d) ("high net worth companies, unincorporated associations, etc.") of the Order (all such persons together being referred to as "relevant persons"). In the United Kingdom, any investment or investment activity to which this communication relates is available only to, and will be engaged in only with, relevant persons. Any person who is not a relevant person should not take any action on the basis of this communication and should not act or rely on it or any of its contents.

This press release may contain forward-looking statements which reflect Fagerhult's current view on future events and financial and operational development. Words such as "intend", "will", "expect", "estimate" and other expressions that imply indications or predictions of future development or trends, constitute forward-looking statements. Forward-looking statements inherently involve both known and unknown risks and uncertainties as they depend on future events and circumstances. Forward-looking statements do not guarantee future results or development and the actual outcome could differ materially from the forward-looking statements. The information, opinions and forward-looking statements included in this press release speak only as of its date and are subject to change without notice.

This information was brought to you by Cision http://news.cision.com

The following files are available for download:

https://mb.cision.com/Main/1781/2810908/1044345.pdf

Fagerhult publishes prospectus supplement relating to the rights issue

 

SOURCE Fagerhult


These press releases may also interest you

25 avr 2024
The Industrial Technology Research Institute (ITRI) convened the 2024 ITRI Net Zero Day in Taipei, accelerating industry's transition to net-zero emissions. The event highlighted key innovations and successful business cases, focusing on the...

25 avr 2024
The report titled "Identity Governance & Administration Market by Component (Services, Solution), Modules (Access Certification & Compliance Control, Access Management, Identity Lifecycle Management), Organization Size, Deployment, Vertical - Global...

25 avr 2024
The report titled "Contract Research Organization Services Market by Type (Clinical Research Services, Consulting Services, Data Management Services), Trial Phase (Phase I, Phase II, Phase III), Therapeutic Area, Molecule Type, End-User - Global...

25 avr 2024
Bristow Group Inc. , the global leader in innovative and sustainable vertical flight solutions, today announced it will release its first quarter 2024 financial results and selected financial outlook for 2025 and 2026 after market close on Tuesday,...

25 avr 2024
AIDS Healthcare Foundation applauds the government of Colombia for issuing a compulsory license on HIV drug dolutegravir, which will allow the country to access affordable generic versions of the treatment as an alternative to the costly branded...

25 avr 2024
SUNRATE, an intelligent global payment and treasury management platform has been named one of the Top 100 Cross-Border Payment Companies for 2024 by FXC Intelligence, which recognises and celebrates the most important players in the cross-border...



News published on and distributed by: